Get the Stockscreener App
2.84
12.35%
-0.40
Genprex Inc stock is traded at $2.84, with a volume of 402.13K.
It is down -12.35% in the last 24 hours and down -38.26% over the past month.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
See More
Previous Close:
$3.24
Open:
$3.17
24h Volume:
402.13K
Relative Volume:
0.60
Market Cap:
$6.45M
Revenue:
-
Net Income/Loss:
$-22.71M
P/E Ratio:
-0.2425
EPS:
-11.71
Net Cash Flow:
$-18.24M
1W Performance:
-15.48%
1M Performance:
-38.26%
6M Performance:
-81.86%
1Y Performance:
-94.64%
1-Day Range:
$2.51
$3.17
1-Week Range:
$2.51
$3.4931
52-Week Range:
$2.51
$63.00
Genprex Inc Stock (GNPX) Company Profile
Name
Genprex Inc
Sector
Industry
Phone
512-537-7997
Address
1601 TRINITY STREET, BLDG. B, AUSTIN, TX
Compare GNPX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GNPX
Genprex Inc
|
2.84 | 7.36M | 0 | -22.71M | -18.24M | -11.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Genprex Inc Stock (GNPX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-26-21 | Initiated | National Securities | Buy |
| Apr-29-19 | Initiated | Noble Capital Markets | Outperform |
Genprex Inc Stock (GNPX) Latest News
MSN Money - MSN
Genprex Secures U.S. Patent for Reqorsa® Therapy - MSN
Genprex Inc Stock Analysis and ForecastSector-Based Investing & High Yield Market Growth - earlytimes.in
Will Genprex Inc. (2DE0) stock recover faster than industry2025 Analyst Calls & Risk Managed Investment Signals - Newser
Is Genprex Inc. (2DE0) stock undervalued after correctionJuly 2025 PreEarnings & Risk Controlled Daily Trade Plans - Newser
Is Genprex Inc. stock cheap at current valuationWeekly Profit Report & Community Driven Trade Alerts - Newser
Congressman Buys Shares Of Small Cap Lift Truck Company You've Probably Never Heard Of - Benzinga
Can Genprex Inc. (2DE0) stock reach $200 price targetEarnings Growth Summary & Entry and Exit Point Strategies - Newser
Get in on Genprex Inc’s (GNPX) buy-in window today! - setenews.com
Why Genprex Inc. stock remains on buy listsWeekly Profit Summary & Fast Gaining Stock Reports - Newser
Genprex, Inc. Stock (GNPX) Opinions on Recent Preclinical Data Release - Quiver Quantitative
Genprex Announces Registered Direct Offering of up to $8.1 Million Priced At-The-Market Under Nasdaq Rules - Aktiellt
Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market Under Nasdaq Rules - Aktiellt
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics (PR Newswire) - Aktiellt
Can Genprex Inc. stock beat market expectations this quarterMarket Activity Recap & Stepwise Entry/Exit Trade Alerts - BỘ NỘI VỤ
Taking the lead: Genprex Inc (GNPX) - Setenews
How Genprex Inc. (2DE0) stock reacts to new regulations2025 Market Trends & Daily Volume Surge Signals - BỘ NỘI VỤ
Genprex regains Nasdaq bid price compliance, receives equity extension By Investing.com - Investing.com Australia
Genprex regains Nasdaq bid price compliance, receives equity extension - Investing.com
Genprex keeps Nasdaq listing with bid-price fix, equity waiver granted - Stock Titan
Genprex reports phase 1 data for lung cancer gene therapy By Investing.com - Investing.com Nigeria
Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Tria - GuruFocus
Genprex (GNPX) Shares Positive Acclaim-1 Trial Data for Lung Can - GuruFocus
Genprex reports phase 1 data for lung cancer gene therapy - Investing.com
Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer - PR Newswire
Genprex files prospectus supplement for up to $75 million at-the-market offering By Investing.com - Investing.com Australia
Genprex files prospectus supplement for up to $75 million at-the-market offering - Investing.com Australia
Genprex Inc. (GNPX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Genprex Announces $75 Million Stock Offering - MSN
[S-1] Genprex, Inc. Files IPO Registration Statement | GNPX SEC FilingForm S-1 - Stock Titan
Genprex, Inc. Announces $75 Million Stock Offering - TradingView
[8-K] Genprex, Inc. Reports Material Event | GNPX SEC FilingForm 8-K - Stock Titan
Can Genprex Inc. (2DE0) stock sustain revenue momentumWeekly Stock Summary & Safe Swing Trade Setup Alerts - newser.com
How Genprex Inc. stock benefits from tech adoption2025 Valuation Update & Reliable Volume Spike Trade Alerts - newser.com
Is Genprex Inc. stock attractive for retirement portfoliosJuly 2025 Breakouts & High Conviction Trade Alerts - newser.com
Why Genprex Inc. (2DE0) stock attracts wealthy investorsPortfolio Gains Summary & Fast Gain Swing Trade Alerts - newser.com
Is Genprex Inc. (2DE0) stock at risk of policy regulationWeekly Profit Report & Expert Approved Momentum Trade Ideas - newser.com
Will Genprex Inc. (2DE0) stock outperform global peersJuly 2025 Gainers & Consistent Growth Equity Picks - newser.com
Published on: 2025-11-19 22:26:30 - newser.com
Genprex Inc Stock (GNPX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):